Skip to main content
. 2020 Jul 14;12(7):661. doi: 10.3390/pharmaceutics12070661

Figure 5.

Figure 5

BBB permeation by the TAMRA-Tat-conjugated peptides was studied in C57BL/6 mice using two-photon fluorescence imaging. (A) Schematic timeline of the experiment, including surgical procedures and peptide administration, followed by administration of 2 MDa FITC-dextran as a control for mechanical damage of the BBB. (B) Second harmonics generation (left), baseline TAMRA-Tat fluorescence (middle), and baseline FITC-dextran fluorescence (right). (C) Time-lapse recordings of relative increases in fluorescence in the brain parenchyma following administration of TAMRA-Tat (top), TAMRA-Tat-NR2B9c (middle), or TAMRA-Tat-N-dimer (3 nmol peptide/g body weight). Scale bar: 100 µm. (D) Kinetic profiles presented as changes in fluorescence of the TAMRA-Tat-conjugated peptides (left) and FITC-dextran (right) in the brain parenchyma and vessels over time. (E) Total change in fluorescence of the TAMRA-Tat-conjugated peptides (left) and FITC-dextran (right) in the brain parenchyma and blood vessels presented as the area under the curve (AUC) obtained from the kinetic profiles. Data are presented as mean ± SEM (N = 5). * p < 0.05, *** p < 0.001 (two-tailed unpaired t-test).